Skip To Main Content
NEXT Madrid on Muck Rack

NEXT Madrid

As seen in: Cancer Research
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with NEXT

Contact NEXT, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

|
By Porto Alegre, Steven Jay, Institut Bergonié, NEXT Madrid
| Cancer Research Verified
This content is only available via PDF. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License .
Open in Who Shared View Duplicates (3) Issue with article?

A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1

|
By New Brunswick, NEXT Madrid, Gonzalez Cao
| Cancer Research Verified
Purpose: Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma. Sotigalimab is a CD40 agonist antibody with unique epitope specificity and Fc-receptor binding profile optimized for activation of CD40-expressing antigen presenting cells. Preclinical data indicated that CD40 agonists combined with anti-PD1 could overcome resistance to anti-PD-1.
Open in Who Shared Issue with article?

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

|
By Institut Claudius Régaud, Institut Jules Bordet, NEXT Madrid
| Cancer Research Verified
Citation Vivek Subbiah, Irene Brana, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla; Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res 2022; clincanres.0696.2022.
Open in Who Shared Issue with article?
See all 3 articles